Point-of-Care Advantage BioMedomics delivers rapid, at‑the‑point‑of‑care diagnostics with lab‑quality reliability. This positions them to target clinics, urgent care centers, and rural health facilities seeking fast turnaround without sending samples to centralized labs.

Sickle Cell & Thalassemia Focus Active participation in ASCAT conferences highlights an emphasis on genetic blood disorders. Target hospitals, research centers, and community clinics serving high HBSC/thalassemia populations for partnerships or distribution of their rapid antibody tests.

COVID Serology Experience Previous partnership with a major player and a proven 15‑minute antibody test capability can be leveraged to pursue collaborations in point‑of‑care respiratory and infectious disease testing, especially in breakout outbreaks or remote settings.

Funding & Scale Gap Revenue in the low millions and modest funding suggest an opportunity to position BioMedomics as a preferred OEM or integrator for larger diagnostics players seeking nimble, cost‑effective point‑of‑care solutions.

Tech Enablement Current tech stack (cloud, web, and standard web frameworks) indicates potential for scalable deployment, telemedicine integration, and data interoperability with hospital information systems to expand adoption and streamline ordering, results delivery, and reporting.